Dopamine agonists in the treatment of prolactinoma: Are they still first choice?

Internal Medicine Journal

Volumn 41, Issue 2, 2011, Pages 156-161

  Ogilvie, C M ^a   Milsom, S R ^a  

^a Reproductive Endocrine Group at Fertility Associates   (New Zealand)

Author keywords

Cardiac valvulopathy; Dopamine agonist; Prolactin; Prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; ORAL CONTRACEPTIVE AGENT; PERGOLIDE; QUINAGOLIDE;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HEADACHE; HEART VALVE REGURGITATION; HUMAN; INSOMNIA; LUNG FIBROSIS; MOOD DISORDER; NAUSEA; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RETROPERITONEAL FIBROSIS; VALVULAR HEART DISEASE; VASOSPASM;

ANIMALS; CHOICE BEHAVIOR; DOPAMINE AGONISTS; HUMANS; PROLACTINOMA; TREATMENT OUTCOME;

EID: 79952034450     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02410.x     Document Type: Article

References (26)

1. Colao A. The prolactinoma. Best Pract Res Clin Endocrinol Metab 2009; 23: 575-96.
2. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997; 82: 2102-7.
3. De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A etal. The treatment with carbergoline for 24months normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol 2006; 64: 307-13.
4. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B etal. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-22.
5. Bronstein MD. Prolactinomas and pregnancy. Pituitary 2005; 8: 31-8.
6. Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hypo responsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005; 8: 53-60.
7. Molitch M. The cabergoline resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 2008; 93: 4643-5.
8. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 43-51.
9. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996; 14: 228-38.
10. Chang SC, Chen CH, Lu ML. Cabergoline induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008; 30: 378-80.
11. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
12. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356: 6-9.
13. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46.
14. Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N etal. The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 2008; 23: 935-41.
15. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67: 1225-9.
16. Valassi E, Klibanski A, Biller BM. Clinical Review: potential cardiac valve effects of dopamine agonists in hyperprolactinaemia. J Clin Endocrinol Metab 2010; 95: 1025-33.
17. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M etal. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93: 3777-84.
18. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot and nonergot derived dopamine agonists. Mov Disord 2009; 15: 129-33.
19. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671-3.
20. Bergh T, Nillius SJ, Wide L. Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol (Copenhagen) 1978; 88: 435-51.
21. Crosignani PG, Ferrari C, Scarduelli C, Picciott MC, Caldara R, Malinverni A. Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol 1981; 58: 708-13.
22. Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA-J Am Med Assoc 1982; 247: 1589-91.
23. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol 2008; 68: 66-71.
24. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-34.
25. Holmgren U, Bergstrand G, Hagenfeldt K etal. Women with prolactinoma - effect of pregnancy and lactation on serum prolactin and on tumor growth. Acta Endocrinol (Copenhagen) 1986; 111: 452-9.
26. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol 2001; 54: 295-300.